1. Home
  2. TRX vs CBIO Comparison

TRX vs CBIO Comparison

Compare TRX & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRX
  • CBIO
  • Stock Information
  • Founded
  • TRX 1990
  • CBIO 2003
  • Country
  • TRX Canada
  • CBIO United States
  • Employees
  • TRX N/A
  • CBIO N/A
  • Industry
  • TRX
  • CBIO
  • Sector
  • TRX
  • CBIO
  • Exchange
  • TRX Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • TRX 228.9M
  • CBIO 209.8M
  • IPO Year
  • TRX N/A
  • CBIO N/A
  • Fundamental
  • Price
  • TRX $0.63
  • CBIO $12.75
  • Analyst Decision
  • TRX Strong Buy
  • CBIO Strong Buy
  • Analyst Count
  • TRX 1
  • CBIO 5
  • Target Price
  • TRX $1.10
  • CBIO $25.60
  • AVG Volume (30 Days)
  • TRX 3.6M
  • CBIO 110.2K
  • Earning Date
  • TRX 11-28-2025
  • CBIO 11-23-2025
  • Dividend Yield
  • TRX N/A
  • CBIO N/A
  • EPS Growth
  • TRX N/A
  • CBIO N/A
  • EPS
  • TRX N/A
  • CBIO N/A
  • Revenue
  • TRX $47,731,000.00
  • CBIO N/A
  • Revenue This Year
  • TRX $23.64
  • CBIO N/A
  • Revenue Next Year
  • TRX $51.77
  • CBIO N/A
  • P/E Ratio
  • TRX $604.90
  • CBIO N/A
  • Revenue Growth
  • TRX 29.98
  • CBIO N/A
  • 52 Week Low
  • TRX $0.27
  • CBIO $9.81
  • 52 Week High
  • TRX $0.85
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • TRX 45.37
  • CBIO 54.35
  • Support Level
  • TRX $0.62
  • CBIO $12.30
  • Resistance Level
  • TRX $0.69
  • CBIO $13.27
  • Average True Range (ATR)
  • TRX 0.05
  • CBIO 0.71
  • MACD
  • TRX -0.02
  • CBIO 0.10
  • Stochastic Oscillator
  • TRX 4.39
  • CBIO 84.97

About TRX TRX Gold Corporation

TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: